文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

发现对急性肾损伤具有抵抗力的队列:来自脓毒性休克患者的启示

Discovery of a resistant cohort to acute kidney injury: insights from patients with septic shock.
PubMed 文献 · Crit Care · 2025-10-08
一句话结论脓毒性休克患者中约7%虽生物标志物高风险却未发生急性肾损伤,其30天死亡率显著低于发生急性肾损伤者(10% vs 32%)。

该研究为对ProCESS试验入组患者的回顾性分析,共573例脓毒性休克患者,在复苏开始后6小时检测尿TIMP-2、IGFBP7和KIM-1。急性肾损伤定义为[TIMP-2]•[IGFBP7] > 1.0 (ng/mL)²/1000且7天内符合KDIGO标准或KIM-1 > 2.0 ng/ml;急性肾损伤抵抗定义为[TIMP-2]•[IGFBP7] > 1.0 (ng/mL)²/1000但既不符合KDIGO标准也无KIM-1 > 2.0 ng/ml。结果示339例(59.2%)为风险降低组,194例(33.9%)发生急性肾损伤,40例(7%)为急性肾损伤抵抗组。急性肾损伤抵抗组30天死亡率显著低于急性肾损伤组(10% vs 32%;校正OR 0.26,95%CI 0.09-0.80,P=0.02),且ICU住院时间更短。作者认为研究这类患者可能揭示急性肾损伤预防和治疗的新靶点。

要点

  • 在脓毒性休克患者中,复苏开始后6小时尿[TIMP-2]•[IGFBP7] > 1.0 (ng/mL)²/1000但未符合KDIGO急性肾损伤标准且KIM-1 ≤ 2.0 ng/ml者被定义为急性肾损伤抵抗,占7%(40/573)。
  • 急性肾损伤抵抗组30天死亡率显著低于急性肾损伤组(10% vs 32%;校正OR 0.26,95%CI 0.09-0.80,P=0.02)。
  • 急性肾损伤抵抗组ICU住院时间短于急性肾损伤组。
  • 急性肾损伤抵抗组与急性肾损伤组基线特征无差异,但非肾脏SOFA评分高于风险降低组(6 [4.5-8] vs 5 [2-7],P < 0.01)。
  • 作者认为研究急性肾损伤抵抗患者可能揭示急性肾损伤预防和治疗的新靶点。

适用人群与场景

  • 对ProCESS试验入组的脓毒性休克患者进行回顾性分析,共573例。
  • 所有患者在复苏开始后6小时检测尿TIMP-2、IGFBP7和KIM-1。

诊断标准与关键阈值

  • 急性肾损伤定义:首先[TIMP-2]•[IGFBP7] > 1.0 (ng/mL)²/1000为高风险,且复苏开始后7天内符合KDIGO标准或KIM-1 > 2.0 ng/ml。
  • 急性肾损伤抵抗定义:[TIMP-2]•[IGFBP7] > 1.0 (ng/mL)²/1000但不符合KDIGO急性肾损伤标准且KIM-1 ≤ 2.0 ng/ml。
  • 风险降低定义:[TIMP-2]•[IGFBP7] < 1.0 (ng/mL)²/1000。

研究设计与关键结果

  • 研究类型:对ProCESS试验入组患者的回顾性分析;样本量573例;人群为脓毒性休克患者。
  • 分组:风险降低组339例(59.2%),急性肾损伤组194例(33.9%),急性肾损伤抵抗组40例(7%)。
  • 非肾脏SOFA评分中位数(IQR):风险降低组5(2-7),急性肾损伤抵抗组6(4.5-8),P < 0.01;急性肾损伤组6(5-9),P < 0.01。
  • 急性肾损伤抵抗组与急性肾损伤组基线特征无差异。
  • 30天死亡率:急性肾损伤抵抗组10% vs 急性肾损伤组32%;校正OR 0.26,95%CI 0.09-0.80,P = 0.02。
  • 急性肾损伤抵抗组ICU住院时间短于急性肾损伤组。
  • 急性肾损伤抵抗组死亡率与住院时间与风险降低组相似,但结局优于急性肾损伤组。

证据类型、等级与局限

  • 证据类型:对ProCESS试验的回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为研究急性肾损伤抵抗患者可能揭示急性肾损伤预防和治疗的新靶点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute kidney injury (AKI) is a significant complication among critically ill patients, particularly those with sepsis, yet no specific therapies exist. Progress in some diseases has been achieved by analyzing individuals who appear resistant. This study sought to develop a framework to investigate AKI resistance using clinical phenotyping and biomarkers and applied this framework to a large cohort of patients with septic shock.

METHODS: We performed a retrospective analysis of patients enrolled in the Protocolized Care for Early Septic Shock (ProCESS) trial. We measured urinary tissue inhibitor of metalloproteinase-2 (TIMP-2), insulin-like growth factor binding protein 7 (IGFBP7), and kidney injury molecule 1 (KIM-1) 6 h after the start of resuscitation. AKI was defined first as high risk by [TIMP-2]•[IGFBP7] > 1.0 (ng/mL)²/1000 and either meeting Kidney Disease Improving Global Outcomes Criteria (KDIGO) criteria within 7 days after the start of resuscitation or having [KIM-1] > 2.0 ng/ml. AKI resistance was defined as the combination of (a) high-risk by [TIMP-2]•[IGFBP7] > 1.0 (ng/mL)²/1000 but without meeting (b) KDIGO AKI criteria nor (c) [KIM-1] > 2.0 ng/ml. We compared clinical characteristics and outcomes across three groups: AKI-resistant, AKI, and reduced risk, which was defined as [TIMP-2]•[IGFBP7] < 1.0 (ng/mL)²/1000.

RESULTS: Among 573 patients, 339 (59.2%) had reduced risk, 194 (33.9%) developed AKI, and 40 (7%) were AKI-resistant. Median (IQR) non-renal SOFA scores were lower for patients at reduced risk for AKI (5 [2-7]) than for those with AKI resistance (6 [4.5-8], P < 0.01) or AKI (6 [5-9], P < 0.01). Baseline characteristics did not differ between AKI-resistant and AKI-affected individuals. However, AKI-resistant patients experienced significantly lower 30-day mortality (10% vs. 32%; adjusted OR 0.26, 95% CI: 0.09-0.80, P = 0.02) and shorter ICU stays when compared to those with AKI.

CONCLUSION: Despite greater illness severity, AKI-resistant patients had similar mortality and length of stay as lower-risk patients but better outcomes than those with AKI. Studying these patients may reveal novel therapeutic targets for AKI prevention and treatment.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Fuhrman DY, Libermann TA, Hukriede NA, et al. Discovery of a resistant cohort to acute kidney injury: insights from patients with septic shock. Crit Care. 2025. PMID: 41063171. doi:10.1186/s13054-025-05647-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。